Rosuvastatin

Rosuvastatin
Clinical data
Pronunciation	/roʊˈsuːvəstætɪn/ ⓘ roh-SOO-və-stat-in
Trade names	Crestor, others
Other names	Rosuvastatin calcium (USAN US)
AHFS/Drugs.com	Monograph
MedlinePlus	a603033
License data	US DailyMed: Rosuvastatin;
Pregnancy; category	AU: D;
Routes of; administration	Oral (by mouth)
ATC code	C10AA07 (WHO) A10BH52 (WHO), C10BX05 (WHO), C10BX09 (WHO), C10BA06 (WHO), C10BA09 (WHO), C10BX16 (WHO), C10BA07 (WHO), C10BX17 (WHO), C10BX10 (WHO), C10BX07 (WHO), C10BX14 (WHO), C10BX13 (WHO), C10BX22 (WHO);
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	20%
Protein binding	88%
Metabolism	Liver: CYP2C9 (major) and CYP2C19-mediated; ~10% metabolized
Metabolites	N-desmethyl rosuvastatin (major; 1/6–1/9 of rosuvastatin activity)
Elimination half-life	19 hours
Excretion	Feces (90%)
Identifiers
	IUPAC name (3R,5S,6E)-7-[4-(4-Fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid;
CAS Number	287714-41-4 ; calcium salt: 147098-20-2 ;
PubChem CID	446157; calcium salt: 5282455;
IUPHAR/BPS	2954;
DrugBank	DB01098 ; calcium salt: DBSALT000154;
ChemSpider	393589 ; calcium salt: 4445607;
UNII	413KH5ZJ73; calcium salt: 83MVU38M7Q ;
KEGG	D08492 ; calcium salt: D01915;
ChEBI	CHEBI:38545 ; calcium salt: CHEBI:77249;
ChEMBL	ChEMBL1496 ; calcium salt: ChEMBL1744447;
PDB ligand	FBI (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID8048492 ;
ECHA InfoCard	100.216.011
Chemical and physical data
Formula	C22H28FN3O6S
Molar mass	481.54 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES OC(=O)C[C@H](O)C[C@H](O)\C=C\c1c(C(C)C)nc(N(C)S(=O)(=O)C)nc1c2ccc(F)cc2;
	InChI InChI=1S/C22H28FN3O6S/c1-13(2)20-18(10-9-16(27)11-17(28)12-19(29)30)21(14-5-7-15(23)8-6-14)25-22(24-20)26(3)33(4,31)32/h5-10,13,16-17,27-28H,11-12H2,1-4H3,(H,29,30)/b10-9+/t16-,17-/m1/s1 ; Key:BPRHUIZQVSMCRT-VEUZHWNKSA-N ;
	(what is this?) (verify)

Rosuvastatin, sold under the brand name Crestor among others, is a statin medication, used to prevent cardiovascular disease in those at high risk and treat abnormal lipids.^[6] It is recommended to be used with dietary changes, exercise, and weight loss.^[6] It is taken orally (by mouth).^[6]

Common side effects include abdominal pain, nausea, headaches, and muscle pains.^[6] Serious side effects may include rhabdomyolysis, liver problems, and diabetes.^[6] Use during pregnancy may harm the baby.^[6] Like all statins, rosuvastatin works by inhibiting HMG-CoA reductase, an enzyme found in the liver that plays a role in producing cholesterol.^[6]

Rosuvastatin was patented in 1991 and approved for medical use in the United States in 2003.^[6]^[7] It is available as a generic medication.^[6] In 2022, it was the thirteenth most commonly prescribed medication in the United States, with more than 37 million prescriptions.^[8]^[9] In Australia, it was one of the top 10 most prescribed medications between 2017 and 2023.^[10]

^ "Rosuvastatin Use During Pregnancy". Drugs.com. 27 September 2019. Archived from the original on 30 November 2020. Retrieved 14 March 2020.
^ "Crestor Product information". Health Canada. 25 April 2012. Archived from the original on 9 July 2021. Retrieved 9 July 2021.
^ "Crestor 10mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 29 September 2020. Archived from the original on 9 July 2021. Retrieved 9 July 2021.
^ ^a ^b Cite error: The named reference Crestor FDA label was invoked but never defined (see the help page).
^ ^a ^b ^c ^d ^e Aggarwal RK, Showkathali R (June 2013). "Rosuvastatin calcium in acute coronary syndromes". Expert Opinion on Pharmacotherapy. 14 (9): 1215–27. doi:10.1517/14656566.2013.789860. PMID 23574635. S2CID 20221457.
^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k ^l ^m ⁿ "Rosuvastatin Calcium Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists (AHFS). Archived from the original on 24 December 2018. Retrieved 24 December 2018.
^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 473. ISBN 9783527607495. Archived from the original on 12 January 2023. Retrieved 27 August 2020.
^ "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
^ "Rosuvastatin Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.
^ "Medicines in the health system". Australian Institute of Health and Welfare. 2 July 2024. Retrieved 30 September 2024.

[Drugs.com_pregnancy-1] "Rosuvastatin Use During Pregnancy". Drugs.com. 27 September 2019. Archived from the original on 30 November 2020. Retrieved 14 March 2020.

[2] "Crestor Product information". Health Canada. 25 April 2012. Archived from the original on 9 July 2021. Retrieved 9 July 2021.

[Crestor_SmPC-3] "Crestor 10mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 29 September 2020. Archived from the original on 9 July 2021. Retrieved 9 July 2021.

[Crestor_FDA_label-4] Cite error: The named reference Crestor FDA label was invoked but never defined (see the help page).

[PK-5] Aggarwal RK, Showkathali R (June 2013). "Rosuvastatin calcium in acute coronary syndromes". Expert Opinion on Pharmacotherapy. 14 (9): 1215–27. doi:10.1517/14656566.2013.789860. PMID 23574635. S2CID 20221457.

[AHFS2018-6] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k ^l ^m ⁿ "Rosuvastatin Calcium Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists (AHFS). Archived from the original on 24 December 2018. Retrieved 24 December 2018.

[Fis2006-7] Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 473. ISBN 9783527607495. Archived from the original on 12 January 2023. Retrieved 27 August 2020.

[8] "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.

[9] "Rosuvastatin Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.

[10] "Medicines in the health system". Australian Institute of Health and Welfare. 2 July 2024. Retrieved 30 September 2024.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]